Pharmaceutical

GE HealthCare to announce second quarter 2024 results on July 31, 2024

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second…

6 months ago

CBIH: Unleashing the Potential of Cannabis for Tomorrow’s Medicine

A letter from our deskHouston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience…

6 months ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024)…

6 months ago

FloraWorks Appoints Dr. Matthew Roberts as Chief Operating Officer to Drive Next Phase of Growth

Portland, Oregon--(Newsfile Corp. - July 8, 2024) - FloraWorks, a leading innovator in the development and commercialization of cannabinoid therapeutics,…

6 months ago

Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz

Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilarsAdditional biosimilars potentially to be added…

6 months ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a…

6 months ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment…

6 months ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to…

6 months ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE…

6 months ago

Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England;…

6 months ago